These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7627885)

  • 1. Prescription drug approval in Canada: a risk-benefit analysis.
    Davis T
    J Can Dent Assoc; 1995 Jul; 61(7):578-9. PubMed ID: 7627885
    [No Abstract]   [Full Text] [Related]  

  • 2. Approval process and access to prescription drugs in Canada.
    Marra CA; Lynd LD; Anis AH; Esdaile JM
    Arthritis Rheum; 2006 Feb; 55(1):9-11. PubMed ID: 16463404
    [No Abstract]   [Full Text] [Related]  

  • 3. New drug approval process in Japan.
    Hayakawa T
    Curr Opin Biotechnol; 1999 Jun; 10(3):307-11. PubMed ID: 10361082
    [No Abstract]   [Full Text] [Related]  

  • 4. China tightens up.
    Qiu J
    Nature; 2007 Aug; 448(7154):636-7. PubMed ID: 17687294
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical policies in Canada: another example of federal-provincial discord.
    Anis AH
    CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new drug evaluation process: risk benefit ratio.
    Somberg JC
    Am J Ther; 2005; 12(3):199-200. PubMed ID: 15891261
    [No Abstract]   [Full Text] [Related]  

  • 7. [The role of the Danish Medical Products Agency in clinical trials].
    Simonsen AC
    Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "New approach" as Health Canada seeks conditional licences for drugs, new pediatric office.
    Eggertson L
    CMAJ; 2005 Mar; 172(7):864. PubMed ID: 15743911
    [No Abstract]   [Full Text] [Related]  

  • 9. [The inspection by the Danish Medical Products Agency of drug clinical trials].
    Jacobsen E; Stilbo I
    Ugeskr Laeger; 2003 Apr; 165(16):1656-8. PubMed ID: 12756822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Editorial Letter. Drug approval].
    Borvendég J
    Neuropsychopharmacol Hung; 2011 Jun; 13(2):54-5. PubMed ID: 21919287
    [No Abstract]   [Full Text] [Related]  

  • 11. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To market, to market. The nuts and bolts of prescription drug approval.
    Peterson AM
    Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443
    [No Abstract]   [Full Text] [Related]  

  • 14. Executed Chinese drug czar corrupted by system, observers say.
    Cyranoski D
    Nat Med; 2007 Aug; 13(8):889. PubMed ID: 17679990
    [No Abstract]   [Full Text] [Related]  

  • 15. China syndrome--a regulatory framework in meltdown?
    Jia H
    Nat Biotechnol; 2007 Aug; 25(8):835-7. PubMed ID: 17687350
    [No Abstract]   [Full Text] [Related]  

  • 16. Hasty approval, more withdrawals.
    Prescrire Int; 2005 Aug; 14(78):144. PubMed ID: 16106597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Walking the drug regulatory tightrope.
    Dove A
    Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing prescription medications for priority regulatory review.
    Rawson NS
    Regul Toxicol Pharmacol; 2005 Jun; 42(1):70-6. PubMed ID: 15896445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. France is set to radically overhaul its drug regulatory system.
    Arie S
    BMJ; 2011 Aug; 343():d4979. PubMed ID: 21816751
    [No Abstract]   [Full Text] [Related]  

  • 20. The Emergency Drug Release Program: regulatory aspects of new drug access in Canada.
    Gilron I
    CMAJ; 1993 Apr; 148(7):1151-3. PubMed ID: 8457955
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.